Effects of mirabegron on JJ stent-related symptoms: A multicentric study
| dc.contributor.author | Cinar O. | |
| dc.contributor.author | Tanidir Y. | |
| dc.contributor.author | Ozer S. | |
| dc.contributor.author | Cizmeci S. | |
| dc.contributor.author | Erbatu O. | |
| dc.contributor.author | Ozdemir T. | |
| dc.contributor.author | Girgin R. | |
| dc.contributor.author | Ongun S. | |
| dc.contributor.author | Ucer O. | |
| dc.contributor.author | Kizilay F. | |
| dc.contributor.author | Sen V. | |
| dc.contributor.author | Irer B. | |
| dc.contributor.author | Bozkurt O. | |
| dc.date.accessioned | 2025-04-10T11:05:46Z | |
| dc.date.available | 2025-04-10T11:05:46Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Aims of the study: To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery. Methods: Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3 weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment. Results: The mean urinary symptoms score decreased significantly from 30.87 ± 9.43 to 22.61 ± 6.78 (P <.0001), mean body pain score decreased significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (P <.0001), mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51 (P <.0001) and mean general health score decreased significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (P <.0001). The mean sexual matters score significantly decreased from 3.88 ± 3.40 to 2.48 ± 2.03 (P <.0001), the additional problem score decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (P <.0001) and the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to 4.23 ± 1.71 after mirabegron use (P <.0001). Conclusion: Daily use of 50 g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life. © 2020 John Wiley & Sons Ltd | |
| dc.identifier.DOI-ID | 10.1111/ijcp.13857 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/46243 | |
| dc.publisher | Blackwell Publishing Ltd | |
| dc.title | Effects of mirabegron on JJ stent-related symptoms: A multicentric study | |
| dc.type | Article |